Citigroup Inc Gossamer Bio, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 2,287,780 shares of GOSS stock, worth $2.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,287,780

Previous 1,705,436 34.15%

Holding current value

$2.2 Million

Previous $1.55 Million 74.02%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.8 - $1.51 $465,875 - $879,339	582,344 Added 34.15%	2,287,780 $2.7 Million
Q4 2023 Feb 09, 2024	BUY	$0.48 - $1.08 $724,177 - $1.63 Million	1,508,704 Added 766.88%	1,705,436 $1.55 Million
Q3 2023 Nov 09, 2023	BUY	$0.78 - $1.82 $151,919 - $354,477	194,768 Added 9916.9%	196,732 $163,000
Q2 2023 Aug 10, 2023	BUY	$0.98 - $1.53 $552 - $862	564 Added 40.29%	1,964 $2,000
Q1 2023 May 11, 2023	SELL	$0.96 - $2.92 $1.16 Million - $3.52 Million	-1,204,145 Reduced 99.88%	1,400 $1,000

Q4 2022 Feb 09, 2023	BUY	$1.74 - $12.87 $226,979 - $1.68 Million	130,448 Added 12.13%	1,205,545 $2.62 Million
Q3 2022 Nov 10, 2022	BUY	$7.21 - $14.88 $1.44 Million - $2.98 Million	200,311 Added 22.9%	1,075,097 $12.9 Million
Q2 2022 Aug 10, 2022	BUY	$5.97 - $9.97 $4.83 Million - $8.06 Million	808,377 Added 1217.27%	874,786 $7.32 Million
Q1 2022 May 12, 2022	SELL	$8.44 - $12.49 $729,013 - $1.08 Million	-86,376 Reduced 56.53%	66,409 $576,000
Q4 2021 Feb 10, 2022	SELL	$10.12 - $14.07 $323,769 - $450,141	-31,993 Reduced 17.31%	152,785 $1.73 Million
Q3 2021 Nov 10, 2021	BUY	$7.25 - $13.23 $1.34 Million - $2.44 Million	184,778 New	184,778 $2.32 Million

Others Institutions Holding GOSS

# of Institutions

114

Shares Held

190M

Call Options Held

405K

Put Options Held

490K

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $90.2M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account